Novel ERBB2 Variant Potentially Associated with Resistance against Anti-HER2 Monoclonal Antibody-Based Therapy in ERBB2-Amplified Metastatic Colorectal Cancer.
Iida N, Imai M, Okamoto W, Kato T, Esaki T, Kato K, Komatsu Y, Yuki S, Masuishi T, Nishina T, Ebi H, Taniguchi H, Nonomura N, Sunakawa Y, Shiozawa M, Yamazaki K, Boku S, Bando H, Shiraishi Y, Kobayashi M, Goto H, Sato A, Fujii S, Yoshino T, Nakamura Y.
Iida N, et al. Among authors: nishina t.
Clin Cancer Res. 2024 Sep 13;30(18):4167-4178. doi: 10.1158/1078-0432.CCR-24-1023.
Clin Cancer Res. 2024.
PMID: 39163021
Free PMC article.